Company: ATRA
Filing Date: 2025-05-16
Form Type: SCHEDULE 13D/A
Source: 0001104659-25-050119
Chunk: 1

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-16
Form: SCHEDULE 13D/A
Chunk 1
---
 Person: (1) Mr. Ciongoli's beneficial ownership of the reported securities is comprised of 1,209,395 shares of Common Stock and 160,686 shares of Common Stock issuable upon exercise of Pre-Funded Warrants which may be exercised as of the date hereof without exceeding the Beneficial Ownership Limitation. The reported securities may also be deemed beneficially owned by Adiumentum Capital Fund I LP and Adiumentum Capital Fund I GP LLC, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Mr. Ciongolie may also be deemed to beneficially own Pre-Funded Warrants held by Adiumentum Capital Fund I LP for 216,507 shares of Common Stock that are not currently exercisable due to the Beneficial Ownership Blocker. Pursuant to the terms of the Pre-Funded Warrants, the Issuer may not effect any exercise of any Pre-Funded Warrant, and a holder of a Pre-Funded Warrant does not have the right to exercise any portion of the Pre-Funded Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 1,209,395 shares of Common Stock and 160,686 shares of Common Stock issuable upon exercise of Pre-Funded Warrants reported as beneficially owned by Mr. Ciongoli in this Schedule 13D represents 19.99% of the outstanding shares of Common Stock. All percentage calculations set forth herein are based upon the aggregate of 6,693,146 shares of Common Stock (as defined below) outstanding as of May 16, 2025, as reported in the Issuer's prospectus supplement filed with the SEC on May 16, 2025, giving effect to the Registered Offering (as defined below) in which 75,572 shares of Common Stock and 227,000 Pre-Funded Warrants were issued to Adiumentum Capital Fund I LP.

| SCHEDULE 13D |

| Item 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Security and Issuer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Common Stock, par value $0.0001 per share                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atara Biotherapeutics, Inc.